valu usd unless otherwis note
view host investor call manag discuss
impact sector follow glenmark
call monday bottom line check continu line impli
modest impact gener opportun side
appear confid pipelin still driver unexpect
surpris unlik favor near-term bia
impact india logist lock-down extend
may drill detail see
meaning suppli disrupt limit api need china
overal suppli chain good shape could short-
term cost increas logist challeng consist other sound
like could opportun pass-through price though
could take month continu ask industri contact
failure-to-suppli ft current environ sound like
latitud particularli suppli uncertain environ
busi heard new cfo taso
konidari appoint last month address guidance/
outlook sens key metric investor focus
ebitda million gener gross margin target
still play also like cash flow
focu new cfo overal outlook come
compani abil get new high valu approv approv
encourag heard front
much constraint leverag think
billion net debt million ebitda midpoint leverag
compani grow ebitda drive cash flow
near-term path lower leverag would uniqu
peer focu busi develop diversif creativ
transact tabl indiffer saw
recent avkar deal opioid front see potenti
deal done next year view exposur small
turn point gener sector possibl first iron
one us domicil larg gener compani amneal
chose tax invert second believ big polit incent
pull back api/finish dosag manufactur us incent
third think government pressur sector subsid
opioid price fix etc overal appear grow polit
support sector move recess sector could
offer biosimilar solut save billion dollar
price prior trade day market close estimate unless otherwis note
mid-cap gener manufactur continu
view favor growth potenti next sever
year execut pipelin complex generics/
biosimilar merger ipxl deliv sizabl pipelin
cost synergi runway add diversif
seen pipelin convers visibl still
challeng addit driver thesi includ
diversifi footprint sizabl pipelin
opportun make market favor
compani midst transit gener
landscap financi flexibl limit
expect focu achiev diversif
beyond gener space come
abil execut
de-lev push given concerns/
pressur lower outlook said
manag team remain focus creativ
transact though balanc sheet constraint
risk view sever primari area
could see stock pressur disrupt combin
busi and/or slower-than-expect synergi
inabl convert pipelin lead near-term ebitda
miss impair target outer yearsvis
low execut drive sentiment faster-than-
anticip eros base busi and/or slower convers
pipelin wrong view move
toward trough cycl headlin risk greater-
than-anticip disrupt
event watch potenti approvals/launch
complex gener copaxon restasi
phase top-lin data initi may
potenti given manag desir
deal updat around opioid gener price fix
bloomberg capit market estim upside/downside/target
base case reflect price-to-earnings ep
addit accret deploy addit
synergi million attain
addit million restructur full benefit
upsid scenario see valu ep
execut accret transact balanc
greater-than-expect launch contribut high-valu
gener product million
upsid million cost synergi ahead
downsid scenario see valu ep
accret deploy cash busi
shortfal term convers key pipelin opportun
and/or failur realiz full econom lead revenu
gross margin shortfal
exhibit
 incom transact close revenu guid millioncost gross profit guid adj gross incom annual paydownoth incom tax incom non-controlling interest incom pro-forma guid share outstanding dilut guid million sharesebitda margin gross improv upper cours pharma gross expect stabil around margin guid adj gross expens incom margin analysi specialti total revenu oper net guid million pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda multipl appli
estim use target multipl respect result
gener valuat framework taken trough price-to-earnings valuat histor averag
ev/ebitda valuat made adjust base company-specif attribut
ev/ebitda incorpor opioid liabil estim within capit structur
impli return price target support sector perform rate
risk rate price target
risk price target rate includ eros base busi compar
assumpt challeng drive growth brand busi delay launch
pipelin opportun greater-thananticip disrupt
amneal specialti pharmaceut compani headquart hayward california
form combin amneal may consist
gener brand segment brand side focus gener portfolio
consist difficult-to-manufactur high barrier-to-entri product across multipl dosag
